Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Air Products & Chemicals, Inc. (APD) vs GSK plc (GSK) Price & Performance

Air Products & Chemicals, Inc.Trade

Price performance (Past 24H)

Key statistics

Air Products & Chemicals, Inc. vs GSK plc — how do they compare? Air Products & Chemicals, Inc. trades at $306.21 (market cap $68.88B), while GSK plc trades at $50.1 (market cap $102.60B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

APDGSK
Market Cap
$68.88B$102.60B
Sector
Basic MaterialsHealth
52-Week High
$314.19$61.18
52-Week Low
$230.42$38.22
Enterprise Value
$86.06B$123.04B
Dividend Yield
2.34%3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Air Products & Chemicals, Inc.

Air Products and Chemicals (APD) trades at $308.18, up 1.56% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS of $3.47 exceeding expectations. Recent positive developments include a major semiconductor supply agreement in Taiwan and raised guidance, though profitability metrics show weakness with negative net income margin and ROE. Analyst consensus remains strongly bullish with a $346 price target representing 12% upside potential.

APD presents a growth opportunity driven by strategic contracts and consistent earnings beats, but faces fundamental challenges with negative profitability and elevated debt levels. The stock's technical strength and institutional support provide near-term momentum, though investors should weigh the disconnect between valuation multiples and current financial performance against the company's long-term growth prospects in industrial gases.

GSK plc

GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.

Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Air Products & Chemicals, Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.

Read more on APD

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK